Difluoromethylornithine in cancer: new advances (Q38765477)

6 September 2017

Difluoromethylornithine in cancer: new advances (English)

1 reference

6 September 2017

George A Alexiou

1

1 reference

6 September 2017

Georgios D Lianos

2

1 reference

6 September 2017

Vassileios Ragos

3

1 reference

6 September 2017

Vasiliki Galani

4

1 reference

6 September 2017

Athanassios P Kyritsis

5

1 reference

6 September 2017

language of work or name

English

0 references

publication date

27 January 2017

1 reference

6 September 2017

1 reference

6 September 2017

13

1 reference

6 September 2017

9

1 reference

6 September 2017

809-819

1 reference

Photodynamic therapy: off-label and alternative use in dermatological practice

6 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

DFMO: targeted risk reduction therapy for colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Inhibitors of polyamine metabolism: review article

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Phase I-II clinical trial with alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Phase I trial of alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Difluoromethylornithine is a novel inhibitor of Helicobacter pylori growth, CagA translocation, and interleukin-8 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Expression profiling and biochemical analysis suggest stress response as a potential mechanism inhibiting proliferation of polyamine-depleted cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Growth regulatory effects of cyclic AMP and polyamine depletion are dissociable in cultured mouse lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Assessing the polyamine metabolism of Plasmodium falciparum as chemotherapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Chemotherapy of human African trypanosomiasis: current and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

JunD stabilization results in inhibition of normal intestinal epithelial cell growth through P21 after polyamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Polyamine analogues - an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Targeting ornithine decarboxylase for the prevention of nonmelanoma skin cancer in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Treatment of recurrent gliomas with eflornithine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

The additive effect of alpha-difluoromethylornithine (DFMO) and radiation therapy on a rat glioma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Difluoromethylornithine: the proof is in the polyamines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

European Code against Cancer, 4th Edition: Cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Estrogen receptor beta as target for colorectal cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Circulating free DNA in plasma or serum as biomarkers of carcinogenesis in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Targeting polyamines and inflammation for cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Polyamine depletion therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

Changes in prostate cancer grading: Including a new patient-centric grading system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0266

21 January 2018

Identifiers

DOI

10.2217/FON-2016-0266

1 reference

6 September 2017

1 reference